Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation.

Muthumani K, Choo AY, Hwang DS, Premkumar A, Dayes NS, Harris C, Green DR, Wadsworth SA, Siekierka JJ, Weiner DB.

Blood. 2005 Sep 15;106(6):2059-68. Epub 2005 May 31.

2.

Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor.

Muthumani K, Wadsworth SA, Dayes NS, Hwang DS, Choo AY, Abeysinghe HR, Siekierka JJ, Weiner DB.

AIDS. 2004 Mar 26;18(5):739-48.

PMID:
15075508
3.

Imidazopyrimidines, potent inhibitors of p38 MAP kinase.

Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC, Fahmy B, Siekierka JJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.

PMID:
12565927
4.

Kinetics of small molecule inhibitor binding to p38 kinase.

Thurmond RL, Wadsworth SA, Schafer PH, Zivin RA, Siekierka JJ.

Eur J Biochem. 2001 Nov;268(22):5747-54.

5.

Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells.

Grant ER, Errico MA, Emanuel SL, Benjamin D, McMillian MK, Wadsworth SA, Zivin RA, Zhong Z.

Biochem Pharmacol. 2001 Aug 1;62(3):283-96.

PMID:
11434901
6.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.

PMID:
10525088
9.

Potent inhibitors of the MAP kinase p38.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3335-40.

PMID:
9873730
10.

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ.

J Med Chem. 1998 Oct 22;41(22):4196-8. No abstract available.

PMID:
9784093
11.

Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production.

Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, Wadsworth SA, Peterson PA, Siekierka JJ, Harris CA, Fung-Leung WP.

J Exp Med. 1998 Jun 15;187(12):2073-9.

12.
13.

Role of the Q10 class I regulatory element region 1 in controlling tissue-specific expression in vivo.

Marine JB, Shirakata Y, Wadsworth SA, Hooley JJ, Handy DE, Coligan JE.

J Immunol. 1993 Aug 15;151(4):1989-97.

PMID:
8345192
14.

Estrogen receptor levels in a murine model of systemic lupus erythematosus.

Athreya BH, Moore WC, Wadsworth SA, Gupta C, Goldman AS.

Clin Exp Rheumatol. 1989 Nov-Dec;7(6):589-93.

PMID:
2612080

Supplemental Content

Loading ...
Support Center